Ibar
The announcement you refer to simply reiterated that the trial was blinded. Nor was there any confirmation of who participated. The reply in my email clearly confirms the patient subject was a participant.
The remarks made by that patient and his partner related to benefits experienced in executive function.
When you listen to the remarks made in the Conference Call in relation to cognition then the patients experience helps support the proposition that measuring the effect of pbt2 for that outcome may prove to be statistically significant.
IbarThe announcement you refer to simply reiterated that the...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $20.98M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $14.55K | 3.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 71906262 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 32338803 | 25 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |